


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Original) A compound represented by Formula I:




Formula I

wherein:

R¹ is optionally substituted aryl or optionally substituted heteroaryl; and
R² is optionally substituted aryl, optionally substituted aralkyl; optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl or optionally substituted heterocyclyl, or a single stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or a solvate of a pharmaceutically acceptable salt thereof.

2. (Original) The compound of Claim 1 where R¹ is represented by Formula II:



wherein:

X is -O-, -O-(optionally substituted lower alkylene)-, -(optionally substituted lower alkylene)-O-, -S-, -S-(optionally substituted lower alkylene)-, -(optionally substituted lower alkylene)-S-, -SO₂-, -SO₂-(optionally substituted lower alkylene)-, or -(optionally substituted lower alkylene)-SO₂-;

Y and Z are independently –C= or –N=, provided that only one of Y or Z is –N=;
R^{1.1} is optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl;
R^{1.2} is hydrogen, halo or optionally substituted heteroaryl; and
R^{1.3} is hydrogen, halo, optionally substituted heteroaryl or nitro.

3. (Original) The compound of Claim 2 having one or more of the following:

X is –O–;
Y and Z are–C=;
R^{1.1} is tetrahydrofuryl, tetrahydropyranyl, optionally substituted pyrrolidinyl, optionally substituted 3-oxo-tetrahydro-pyrrolo[1,2-c]oxazol-6-yl, optionally substituted morpholinyl, optionally substituted piperidinyl, optionally substituted pyridinyl or optionally substituted phenyl;
R^{1.2} is hydrogen or fluoro; and
R^{1.3} is pyridinyl or fluoro.

4. (Original) The compound of Claim 3 where:

Y and Z are–C=;
R^{1.1} is tetrahydrofuryl, tetrahydropyranyl, substituted-pyrrolidinyl, 3-oxo-tetrahydro-pyrrolo[1,2-c]oxazol-6-yl, substituted-piperidinyl, pyridinyl or hydroxy-lower alkyl-phenyl;
R^{1.2} is hydrogen; and
R^{1.3} is fluoro.

5. (Original) The compound of Claim 4 where X is –O–.

6. (Original) The compound of Claim 2 where R^{1.1} is 1-acyl-pyrrolidin-3-yl, 1-alkoxycarbonyl-pyrrolidin-3-yl, 1-amidino-pyrrolidin-3-yl, 1-sulfonyl-pyrrolidin-3-yl, 3-oxo-

tetrahydro-pyrrolo[1,2-c]oxazol-6-yl, 1-acyl-piperidin-3-yl, 1-alkoxycarbonyl-piperidin-3-yl, 1-amidino-piperidin-3-yl or 1-sulfonyl-piperidin-3-yl, optionally having an additional lower alkoxy or lower alkoxyalkyl ring substituent.

7. (Original) The compound of Claim 3 where R^{1.1} is 1-acyl-pyrrolidin-3-yl, 1-alkoxycarbonyl-pyrrolidin-3-yl, 1-amidino-pyrrolidin-3-yl, 1-sulfonyl-pyrrolidin-3-yl, 3-oxo-tetrahydro-pyrrolo[1,2-c]oxazol-6-yl, 1-acyl-piperidin-3-yl, 1-alkoxycarbonyl-piperidin-3-yl, 1-amidino-piperidin-3-yl or 1-sulfonyl-piperidin-3-yl, optionally having an additional lower alkoxy or lower alkoxyalkyl ring substituent.

8. (Original) The compound of Claim 4 where R^{1.1} is 1-acyl-pyrrolidin-3-yl, 1-alkoxycarbonyl-pyrrolidin-3-yl, 1-amidino-pyrrolidin-3-yl, 1-sulfonyl-pyrrolidin-3-yl, 3-oxo-tetrahydro-pyrrolo[1,2-c]oxazol-6-yl, 1-acyl-piperidin-3-yl, 1-alkoxycarbonyl-piperidin-3-yl, 1-amidino-piperidin-3-yl or 1-sulfonyl-piperidin-3-yl, optionally having an additional lower alkoxy or lower alkoxyalkyl ring substituent.

9. (Original) The compound of Claim 5 where R^{1.1} is 1-acyl-pyrrolidin-3-yl, 1-alkoxycarbonyl-pyrrolidin-3-yl, 1-amidino-pyrrolidin-3-yl, 1-sulfonyl-pyrrolidin-3-yl, 3-oxo-tetrahydro-pyrrolo[1,2-c]oxazol-6-yl, 1-acyl-piperidin-3-yl, 1-alkoxycarbonyl-piperidin-3-yl, 1-amidino-piperidin-3-yl or 1-sulfonyl-piperidin-3-yl, optionally having an additional lower alkoxy or lower alkoxyalkyl ring substituent.

10. (Original) The compound of Claim 5 where R^{1.1} is 1-acetyl-piperidin-3-yl, 1-methoxyacetyl-piperidin-3-yl, 1-(azetidine-1-carbonyl)-piperidin-3-yl, 1-methoxycarbonyl-piperidin-3-yl, 1-ethoxycarbonyl-piperidin-3-yl, 1-dimethylaminocarbonyl-piperidin-3-yl, 1-methanesulfonyl-piperidin-3-yl, 1-(ethane-2-sulfonyl)-piperidin-3-yl, 1-(propane-2-sulfonyl)-piperidin-3-yl, 1-(azetidin-1-yl-sulfonyl)-piperidin-3-yl, 1-dimethylaminosulfonyl-piperidin-3-yl, 1-(N¹-azetidin-1-yl-N²-cyano-amidino)-piperidin-3-yl, 1-(N²-cyano-N¹,N¹-dimethylamidino)-piperidine-3-yl, 1-acetyl-pyrrolidin-3-yl, 1-methoxyacetyl-pyrrolidin-3-yl, 1-(azetidine-1-carbonyl)-pyrrolidin-3-yl, 1-methoxycarbonyl-pyrrolidin-3-yl,

1-methoxycarbonyl-2-methoxymethyl-pyrrolidin-4-yl, 1-methanesulfonyl-pyrrolidin-3-yl, 1-(ethane-2-sulfonyl)-pyrrolidin-3-yl, 1-(ethane-2-sulfonyl)-4-methoxy-pyrrolidin-3-yl, 1-(ethane-2-sulfonyl)-5-methoxymethyl-pyrrolidin-3-yl, 1-(propane-2-sulfonyl)-pyrrolidin-3-yl, 1-(azetidin-1-yl-sulfonyl)-pyrrolidin-3-yl, 1-dimethylaminosulfonyl-pyrrolidin-3-yl, 1-dimethylaminosulfonyl-2-methoxymethyl-pyrrolidin-4-yl, 1-(N^1 -azetidin-1-yl- N^2 -cyano-amidino)-pyrrolidin-3-yl, 1-(N^2 -cyano- N^1,N^1 -dimethyamidino)-pyrrolidin-3-yl, or 3-oxo-tetrahydro-pyrrolo[1,2-c]oxazol-6-yl.

11. (Original) The compound of Claim 10 where R^{1,1} is 1-acyl-pyrrolidin-3-yl, 1-sulfonyl-pyrrolidin-3-yl, 3-oxo-tetrahydro-pyrrolo[1,2-c]oxazol-6-yl, 1-alkoxycarbonyl-piperidin-3-yl or 1-sulfonyl-piperidin-3-yl.

12. (Original) The compound of Claim 11 where R^{1,1} is 1-methoxycarbonyl-2-methoxymethyl-pyrrolidin-4-yl, 1-(ethane-2-sulfonyl)-pyrrolidin-3-yl, 1-(ethane-2-sulfonyl)-5-methoxymethyl-pyrrolidin-3-yl, 1-dimethylaminosulfonyl-pyrrolidin-3-yl, 1-dimethylaminosulfonyl-2-methoxymethyl-pyrrolidin-4-yl, 3-oxo-tetrahydro-pyrrolo[1,2-c]oxazol-6-yl, 1-methoxycarbonyl-piperidin-3-yl, 1-methanesulfonyl-piperidin-3-yl, or 1-(ethane-2-sulfonyl)-piperidin-3-yl.

13. (Currently amended) The compound of ~~any~~ of Claim[[s]] 1[[[-12]]] where R² is optionally substituted aryl or optionally substituted heteroaryl.

14. (Original) The compound of Claim 13 where R² is optionally substituted phenyl, optionally substituted naphthyl, optionally substituted pyrrolyl, optionally substituted, thiazolyl, optionally substituted isooxazolyl, optionally substituted pyrazolyl, optionally substituted pyridinyl, optionally substituted pyrazinyl, optionally substituted pyrimidinyl, or optionally substituted pyridazinyl.

15. (Original) The compound of Claim 13 where R² has one or two optional substituents selected from: acetyl, lower alkyl, lower alkoxy, lower alkoxyalkyl, lower

alkoxy carbonyl, hydroxy lower alkyl, alkoxy lower alkyl, carboxy, halo and trifluoromethyl.

16. (Original) The compound of Claim 15 where R² is isooxazol-3-yl, 5-methyl-isooxazol-3-yl, isooxazol-5-yl, pyrazol-3-yl, pyrazinyl, substituted phenyl or optionally substituted pyridinyl.

17. (Original) The compound of Claim 16 where R² is:
phenyl having one or two substituents selected from: lower alkyl, lower alkoxy, halo, hydroxy and hydroxy lower alkyl; or

pyridin-2-yl, pyridin-3-yl or pyridin-4-yl optionally having a substituent selected from: acetyl, lower alkyl, lower alkoxy, lower alkoxyalkyl, lower alkoxy carbonyl, carboxy and trifluoromethyl.

18. (Original) The compound of Claim 17 where R² is optionally-p-substituted pyridin-3-yl.

19. (Original) The compound of Claim 18 where R² is pyridin-3-yl optionally p-substituted with a member of the group: acetyl, methyl, ethyl, methoxy, methoxymethyl, hydroxy, hydroxymethyl and hydroxyethyl.

20. (Original) The compound of Claim 19 where R² is pyridin-3-yl or 6-methyl-pyridin-3-yl.

21. (Currently amended) The compound of any of Claim[[s]] 1[[-12]] where R² is optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted heteroaralkyl or optionally substituted heterocyclyl.

22. (Original) The compound of Claim 21 where R² is represented by the formula -W-R^{2,1} where:

W is C₁ to C₃ straight or branched-chain alkylene; and
R^{2,1} is tetrahydrofuryl, tetrahydropyranyl, optionally substituted pyrrolidinyl,
optionally substituted morpholinyl, optionally substituted piperidinyl, optionally
substituted pyridinyl or optionally substituted phenyl.

23. (Original) The compound of Claim 22 where:

W is methylene; and
R^{2,1} is tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, N-acyl-pyrrolidin-2-yl, N-acyl-
morpholin-3-yl, N-acyl-piperidin-3-yl, N-acyl-piperidin-4-yl, pyridin-3-yl, pyridin-4-yl,
optionally substituted piperidinyl *p*-methoxy-phenyl or *p*-fluoro-phenyl.

24. (Original) The compound of Claim 21 where R² is tetrahydrofuran-2-yl,
tetrahydrofuran-3-yl, N-acyl-pyrrolidin-2-yl, N-acyl-morpholin-3-yl, N-acyl-piperidin-3-yl,
N-acyl-piperidin-4-yl or cyclohexyl.

25. (Currently amended) A compound selected from the group:

1-[3-(1-Acetyl-piperidin-3-yloxy)-5-fluoro-phenyl]-3-(6-methoxy-pyridin-3-yl)-urea;
1-[3-(1-Acetyl-piperidin-3-yloxy)-5-fluoro-phenyl]-3-pyridin-3-yl-urea;
1-[3-Fluoro-5-(1-methanesulfonyl-piperidin-3-yloxy)-phenyl]-3-pyridin-3-yl-urea;
1-[3-Fluoro-5-(3-pyridin-3-yl-ureido)-phenoxy]-piperidine-1-carboxylic acid methyl
ester;
(R)-1-[3-(1-Acetyl-piperidin-3-yloxy)-5-fluoro-phenyl]-3-(6-methoxy-pyridin-3-yl)-
urea;
(R)-1-[3-(1-Acetyl-piperidin-3-yloxy)-5-fluoro-phenyl]-3-pyridin-3-yl-urea;
(R)-1-[3-Fluoro-5-(3-pyridin-3-yl-ureido)-phenoxy]-piperidine-1-carboxylic acid
methyl ester;
(R)-1-[3-Fluoro-5-(3-pyridin-3-yl-ureido)-phenoxy]-piperidine-1-carboxylic acid
dimethylamide;
(R)-1-[3-Fluoro-5-(1-methanesulfonyl-piperidin-3-yloxy)-phenyl]-3-pyridin-3-yl-
urea;

(R)-1-[3-(1-Acetyl-piperidin-3-yloxy)-5-fluoro-phenyl]-3-(6-methyl-pyridin-3-yl)-urea;

(R)-1-{3-Fluoro-5-[3-(6-methyl-pyridin-3-yl)-ureido]-phenoxy}-piperidine-1-carboxylic acid methyl ester;

(R)-1-{3-Fluoro-5-[3-(6-methyl-pyridin-3-yl)-ureido]-phenoxy}-piperidine-1-carboxylic acid dimethylamide;

(R)-1-[3-Fluoro-5-(1-methanesulfonyl-piperidin-3-yloxy)-phenyl]-3-(6-methyl-pyridin-3-yl)-urea;

(R)-1-[3-Fluoro-5-(3-pyridin-3-yl-ureido)-phenoxy]-piperidine-1-carboxylic acid ethyl ester;

(R)-1-[3-Fluoro-5-(3-pyridin-3-yl-ureido)-phenoxy]-piperidine-1-sulfonic acid dimethylamide;

(R)-1-{3-Fluoro-5-[3-(6-methyl-pyridin-3-yl)-ureido]-phenoxy}-piperidine-1-sulfonic acid dimethylamide;

(R)-1-{3-Fluoro-5-[1-(propane-2-sulfonyl)-piperidin-3-yloxy]-phenyl}-3-pyridin-3-yl-urea;

(R)-1-{3-Fluoro-5-[1-(propane-2-sulfonyl)-piperidin-3-yloxy]-phenyl}-3-(6-methyl-pyridin-3-yl)-urea;

(R)-1-[3-(1-Ethanesulfonyl-piperidin-3-yloxy)-5-fluoro-phenyl]-3-pyridin-3-yl-urea;

(R)-1-[3-(1-Ethanesulfonyl-piperidin-3-yloxy)-5-fluoro-phenyl]-3-(6-methyl-pyridin-3-yl)-urea;

(S)-3-[3-Fluoro-5-(pyridin-3-yl-ureido)-phenoxy]-piperidine-1-N,N-dimethyl-N-cyano-carboxamidine;

(S)-3-[3-Fluoro-5-(2-methyl-pyridin-5-yl-ureido)-phenoxy]-piperidine-1-N,N-dimethyl-N-cyano-carboxamidine;

(S)-1-[3-Fluoro-5-(3-pyridin-3-yl-ureido)-phenoxy]-piperidine-1-sulfonic acid dimethylamide;

(S)-1-{3-Fluoro-5-[3-(6-methyl-pyridin-3-yl)-ureido]-phenoxy}-piperidine-1-sulfonic acid dimethylamide;

(S)-1-[3-(1-Ethanesulfonyl-piperidin-3-yloxy)-5-fluoro-phenyl]-3-pyridin-3-yl-urea;

(S)-1-{3-Fluoro-5-[1-(propane-2-sulfonyl)-piperidin-3-yloxy]-phenyl}-3-pyridin-3-yl-urea;

(S)-1-[3-Fluoro-5-(3-pyridin-3-yl-ureido)-phenoxy]-piperidine-1-carboxylic acid methyl ester;

(S)-1-[3-Fluoro-5-(3-pyridin-3-yl-ureido)-phenoxy]-piperidine-1-carboxylic acid ethyl ester;

(S)-1-[3-(1-Ethanesulfonyl-piperidin-3-yloxy)-5-fluoro-phenyl]-3-(6-methyl-pyridin-3-yl)-urea;

(S)-1-{3-Fluoro-5-[1-(propane-2-sulfonyl)-piperidin-3-yloxy]-phenyl}-3-(6-methyl-pyridin-3-yl)-urea;

(S)-1-{3-Fluoro-5-[3-(6-methyl-pyridin-3-yl)-ureido]-phenoxy}-piperidine-1-carboxylic acid methyl ester;

(S)-1-{3-Fluoro-5-[3-(6-methyl-pyridin-3-yl)-ureido]-phenoxy}-piperidine-1-carboxylic acid ethyl ester; and

(S)-1-[3-Fluoro-5-(1-methanesulfonyl-piperidin-3-yloxy)-phenyl]-3-pyridin-3-yl-urea,

or a single stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or a solvate of a pharmaceutically acceptable salt thereof.

26. (Currently amended) A compound selected from the group:

(S)-3-{3-Fluoro-5-[3-(6-methyl-pyridin-3-yl)-ureido]-phenoxy}-pyrrolidine-1-sulfonic acid dimethylamide;

(R)-3-{3-Fluoro-5-[3-(6-methyl-pyridin-3-yl)-ureido]-phenoxy}-pyrrolidine-1-sulfonic acid dimethylamide;

(S)-3-[3-Fluoro-5-(2-methyl-pyridin-5-yl-ureido)-phenoxy]-pyrrolidine-1-N,N-dimethyl-N-cyano-carboxamidine;

(R)-3-[3-Fluoro-5-(2-methyl-pyridin-5-yl-ureido)-phenoxy]-pyrrolidine-1-N,N-dimethyl-N-cyano-carboxamidine;

(S)-3-[3-Fluoro-5-(3-pyridin-3-yl-ureido)-phenoxy]-pyrrolidine-1-sulfonic acid dimethylamide;

(S)-3-[3-Fluoro-5-(pyridin-2-yl-ureido)-phenoxy]-pyrrolidine-1-N,N-dimethyl-N-cyano-carboxamidine;

(R)-3-[3-Fluoro-5-(3-pyridin-3-yl-ureido)-phenoxy]-pyrrolidine-1-sulfonic acid dimethylamide;

(R)-3-[3-Fluoro-5-(pyridin-2-yl-ureido)-phenoxy]-pyrrolidine-1-N,N-dimethyl-N-cyano-carboxamidine;

(S)-3-[3-Fluoro-5-(3-pyridin-3-yl-ureido)-phenoxy]-pyrrolidine-1-carboxylic acid methyl ester;

(S)-3-{3-Fluoro-5-[3-(6-methyl-pyridin-3-yl)-ureido]-phenoxy}-pyrrolidine-1-carboxylic acid methyl ester;

(R)-3-{3-Fluoro-5-[3-(6-methyl-pyridin-3-yl)-ureido]-phenoxy}-pyrrolidine-1-carboxylic acid methyl ester;

(R)-3-[3-Fluoro-5-(3-pyridin-3-yl-ureido)-phenoxy]-pyrrolidine-1-carboxylic acid methyl ester;

(S)-1-{3-Fluoro-5-[1-(propane-2-sulfonyl)-pyrrolidin-3-yloxy]-phenyl}-3-pyridin-3-yl-urea;

(S)-1-{3-Fluoro-5-[1-(propane-2-sulfonyl)-pyrrolidin-3-yloxy]-phenyl}-3-(6-methyl-pyridin-3-yl)-urea;

(S)-1-{3-Fluoro-5-[1-(ethane-2-sulfonyl)-pyrrolidin-3-yloxy]-phenyl}-3-pyridin-3-yl-urea;

(S)-1-{3-Fluoro-5-[1-(ethane-2-sulfonyl)-pyrrolidin-3-yloxy]-phenyl}-3-(6-methyl-pyridin-3-yl)-urea;

(R)-1-{3-Fluoro-5-[1-(ethane-2-sulfonyl)-pyrrolidin-3-yloxy]-phenyl}-3-pyridin-3-yl-urea;

(S)-1-{3-Fluoro-5-[1-(methane-2-sulfonyl)-pyrrolidin-3-yloxy]-phenyl}-3-(6-methyl-pyridin-3-yl)-urea;

(R)-1-{3-Fluoro-5-[1-(ethane-2-sulfonyl)-pyrrolidin-3-yloxy]-phenyl}-3-(6-methyl-pyridin-3-yl)-urea;

(R)-1-{3-Fluoro-5-[1-(propane-2-sulfonyl)-pyrrolidin-3-yloxy]-phenyl}-3-(6-methyl-pyridin-3-yl)-urea;

(S)-4-{3-Fluoro-5-[3-(6-methyl-pyridin-3-yl)-ureido]-phenoxy}-[(S)-2-methoxymethyl]-pyrrolidine-1-sulfonic acid dimethylamide;

(S)-4-{3-Fluoro-5-[3-(6-methyl-pyridin-3-yl)-ureido]-phenoxy}-[(S)-2-methoxymethyl]-pyrrolidine-1-carboxylic acid methyl ester;

(R)-1-{3-(1-Ethanesulfonyl-[(R)-4-methoxy]-pyrrolidin-3-yloxy)-5-fluoro-phenyl}-3-(6-methyl-pyridin-3-yl)-urea;

(R)-1-{3-(1-Ethanesulfonyl-[(S)-5-methoxymethyl]-pyrrolidin-3-yloxy)-5-fluoro-phenyl}-3-pyridin-3-yl-urea;

(R)-1-{3-(1-Ethanesulfonyl-[(S)-5-methoxymethyl]-pyrrolidin-3-yloxy)-5-fluoro-phenyl}-3-(6-methyl-pyridin-3-yl)-urea;

1-[3-Fluoro-5-(R)-(3-oxo-(S)-tetrahydro-pyrrolo[1,2-c]oxazol-6-yloxy)-phenyl]-3-pyridin-3-yl-urea; and

1-[3-Fluoro-5-(R)-(3-oxo-(S)-tetrahydro-pyrrolo[1,2-c]oxazol-6-yloxy)-phenyl]-3-(6-methyl-pyridin-3-yl)-urea,

or a single stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or a solvate of a pharmaceutically acceptable salt thereof.

27. (Currently amended) A compound selected from the group:

(S)-1-[3-(1-Ethanesulfonyl-piperidin-3-yloxy)-5-fluoro-phenyl]-3-(6-methyl-pyridin-3-yl)-urea;

(S)-1-{3-Fluoro-5-[3-(6-methyl-pyridin-3-yl)-ureido]-phenoxy}-piperidine-1-carboxylic acid methyl ester;

(S)-1-[3-Fluoro-5-(1-methanesulfonyl-piperidin-3-yloxy)-phenyl]-3-pyridin-3-yl-urea;

(R)-3-[3-Fluoro-5-(3-pyridin-3-yl-ureido)-phenoxy]-pyrrolidine-1-sulfonic acid dimethylamide;

(R)-1-{3-Fluoro-5-[1-(ethane-2-sulfonyl)-pyrrolidin-3-yloxy]-phenyl}-3-(6-methyl-pyridin-3-yl)-urea;

(S)-4-{3-Fluoro-5-[3-(6-methyl-pyridin-3-yl)-ureido]-phenoxy}-[(S)-2-methoxymethyl]-pyrrolidine-1-sulfonic acid dimethylamide;

(S)-4-{3-Fluoro-5-[3-(6-methyl-pyridin-3-yl)-ureido]-phenoxy}-[(S)-2-methoxymethyl]-pyrrolidine-1-carboxylic acid methyl ester;

(R)-1-{3-(1-Ethanesulfonyl-[(S)-5-methoxymethyl]-pyrrolidin-3-yloxy)-5-fluoro-phenyl}-3-pyridin-3-yl-urea;

1-[3-Fluoro-5-(R)-(3-oxo-(S)-tetrahydro-pyrrolo[1,2-c]oxazol-6-yloxy)-phenyl]-3-pyridin-3-yl-urea; and

1-[3-Fluoro-5-(R)-(3-oxo-(S)-tetrahydro-pyrrolo[1,2-c]oxazol-6-yloxy)-phenyl]-3-(6-methyl-pyridin-3-yl)-urea;

or a single stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or a solvate of a pharmaceutically acceptable salt thereof.

28. (Currently amended) A method of treatment for heart failure, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound, single stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or a solvate of a pharmaceutically acceptable salt of ~~any of Claim[[s]] 1[-12]]~~.

29. - 41. (Cancelled)

42. (Currently amended) A pharmaceutical formulation comprising a pharmaceutically accepted excipient and a therapeutically effective amount of a compound, single stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, solvate, or a solvate of a pharmaceutically acceptable salt of ~~any of Claim[[s]] 1[-12]]~~.

43. - 55. (Cancelled)